ABSTRACT
Background Upper limb vascular trauma (ULVT) is a prevalent injury associated with significant morbidity and mortality. Despite its clinical importance, epidemiological studies on ULVT are scarce, particularly in developing countries where the incidence may be heightened by factors such as traffic accidents and violence.
Objective To analyze the epidemiology of ULVT across Brazil, a developing country, evaluating incidence rates, demographic characteristics, mortality rates, days of hospitalization, and related healthcare costs.
Methods A cross-sectional, retrospective analysis using data from the Brazilian public health system (SUS) over a sixteen-year period (2008-2023). The automated data extraction utilized Python-based tools to gather information on vascular trauma procedures identified by ICD-10 codes. Statistical analyses were performed to assess variations in incidence, mortality, and treatment costs across Brazilian regions.
Results A total of 25,573 cases of ULVT were recorded, representing approximately 0.02% of the studied population. The majority of cases occurred in males (79.8%) with a mean age of 34.71 years, with a peak incidence in the 20-24 age group. The region in Brazil with the highest incidence of ULVT was the North (16.6 cases per 100,000 inhabitants) and the region with the lowest was the Southeast (10.7 cases per 100,000 inhabitants). The average hospital stay was 4.39 days and 92,8% of patients did not need to be admitted to an intensive care unit (ICU). Of the patients admitted to the ICU, the average length of stay was 4.52 days. Overall lethality (deaths per cases of ULVT) was 2.37%, with higher lethality observed in bilateral ULVT cases (3.81%).
Conclusions ULVT is more prevalent in Brazil than in developed countries, even when adjusted for population size. However, mortality rates and hospitalization durations do not appear to differ significantly from those in developed countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at DATASUS (Department of Information and Informatics of the brazilian public health system) https://datasus.saude.gov.br/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos